Zepbound produced the largest weight reductions of any approved drug in this class. The interesting development is that Eli Lilly now sells it for less than several telehealth services charge for a compounded copy.
Published: single-dose vials at $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg through 15 mg, with KwikPens spanning the same $299 to $449 range. No membership, no programme fee — you pay per medication.
The comparison people usually skip: Measured charges $268 all-in for compounded tirzepatide, Eden $298, OrderlyMeds $299 standard. At $299 for the 2.5 mg starting dose, LillyDirect is at or below all three for an FDA-approved product with published trial data and manufacturer-controlled quality.
Tirzepatide at a starting dose: approved product against compounded copies
| Source | 2.5 mg monthly | Regulatory status |
|---|---|---|
| CoreAge Rx (compounded, 12-month plan) | $129 monthly equivalent | Not FDA-approved or evaluated |
| Coby Health (compounded) | $239 | Not FDA-approved or evaluated |
| Measured (compounded, all-in) | $268 | Not FDA-approved or evaluated |
| LillyDirect (Zepbound) | $299 | FDA-approved, manufacturer-supplied |
| Eden (compounded, all-in) | $298 | Not FDA-approved or evaluated |
| Eden (branded resale) | $1,399 | FDA-approved, resold |
Scroll the table sideways to see every column.
Where the gap reopens
At maintenance doses. $449 from 7.5 mg upward is a real premium over CoreAge Rx's flat $129 or HealthiCare's $144, and most people titrate past 5 mg. So the honest version is that LillyDirect is highly competitive at the start of treatment and roughly three times the cheapest compounded option once you are established.
Whether that premium is worth paying is a question about what you are buying. Compounded tirzepatide is a pharmacy preparation with no FDA evaluation of safety, effectiveness or quality, sold on trial results generated by this product. $449 buys the thing the trials actually studied.
Where a dose sits on the studied ladder
Move the slider to see whether a dose is one the weight-loss trials actually used. Doses below the studied range may still suit you — they simply have no trial result attached.
Standard titration step
Standard schedule: Weeks 1–4
The standard starting dose. Intended to build tolerance, not to produce weight loss.
In the trial programme behind Wegovy, adults reached a 2.4 mg weekly maintenance dose and lost an average of about 15% of body weight over 68 weeks.
Titration schedules are the standard ones for the approved products and are shown for orientation, not as a dosing instruction. Compounded products are not FDA-approved and your prescriber sets your schedule. Never change a dose on the basis of a web page.
What Zepbound is, and what it costs at source
Zepbound is tirzepatide, approved by FDA for chronic weight management, and it produced the largest average reductions of any drug in this class — roughly 20 to 21% of body weight over 72 weeks at the highest doses. It is also approved for obstructive sleep apnoea in adults with obesity, which occasionally unlocks coverage where a weight-only prescription would be refused.
Eli Lilly sells it directly. LillyDirect publishes single-dose vials at $299 a month for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg through 15 mg, with KwikPens across the same range. That is the reference price, and it is close enough to mid-market compounded tirzepatide that the comparison is worth running properly.
Before you buy branded from a reseller
- Check the manufacturer's own price first — NovoCare for Wegovy, LillyDirect for Zepbound. Resale prices range across an order of magnitude.
- Establish whether a membership or programme fee is charged on top of the medication.
- Ask what the price is at your expected maintenance dose, since branded pricing usually rises with dose.
- If you have type 2 diabetes, ask about Ozempic or Mounjaro through insurance before paying cash for anything.
- Confirm whether the provider will submit a prior authorisation, and what happens if it is denied.